Thiogenesis Therapeutics (TSXV:TTI) Long-Term Debt : C$0.00 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Long-Term Debt?

Thiogenesis Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2024 was C$0.00 Mil.

Thiogenesis Therapeutics Long-Term Debt Historical Data

The historical data trend for Thiogenesis Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Long-Term Debt Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Long-Term Debt

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial											-	-	-	-	-

Thiogenesis Therapeutics (TSXV:TTI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Thiogenesis Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder